Wearable Sensory Prosthesis to Improve Coordination, Walking, and Physical Activity
RxFunction Inc. · with Brooks Rehabilitation · NCT07554443
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 60+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 18
- US sites recruiting
- 1
- Study start
- June 25, 2026
- Record last updated
- June 25, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to investigate whether sensory stimulations from a neuroprosthesis device (Walkasins®) can increase physical activity and improve gait quality in persons with peripheral neuropathy (PN). The main question it aims to answer is whether Walkasins enhances habitual activity patterns in adults with peripheral neuropathy.
Participants will do the following as part of the study:
- Complete a sensation and balance assessment to determine eligibility for the study.
- Answer questions about their medical history, physical function, balance confidence, and sleep.
- Perform various balance and walking tasks on three separate occasions. One of the tests involves walking for six minutes without a cane or walker.
- Wear an activPAL activity monitor for ten days on three separate occasions and return it to the researcher as directed.
- Wear Walkasins for ten weeks as part of their daily routine. Walkasins consists of two parts: 1) an insole that fits inside the shoe and 2) a strap that secures around the ankle.
Being studied: External, lower limb sensory prosthesis
Conditions: Peripheral Neuropathy With Type 2 Diabetes; Peripheral Neuropathy Grade 2 or Greater; Balance; Balance Impairment, Gait Disorders, Fatigue; Balance Disorders; Physical Activities
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Be 60 years of age or older
- Have a diagnosis of PN with plantar sensory loss
- Demonstrate balance impairment, defined as a Single-Leg Stance time of \<23 seconds
- Be able to walk independently for at least 6 minutes without the use of an assistive device (rest breaks permitted)
- Be willing to use the Walkasins device as recommended
- Be willing to participate in all aspects of physical activity monitoring and study assessments
Exclusion Criteria
- Under 60 years old
- Do not have a diagnosis of PN with plantar sensory loss
- Self-reported acute thrombophlebitis, including deep vein thrombosis
- Self-reported severe peripheral vascular disease
- Untreated lymphedema
- Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use
- Self-reported, untreated fractures in the foot and ankle
- Other neurological or musculoskeletal conditions that moderately or severely impact walking
- Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins
- Weight of more than 300 pounds
- Inability to perceive vibration from Walkasins Haptic Module
- Do not demonstrate balance impairments, defined as a Single-Leg Stance time of \<23 seconds
Recruiting US locations
Brooks Rehabilitation Center
Jacksonville, FL 32216
Site contact: Mark B Bowden, PhD · 904.345.6626 · research@rxfunction.com
Study contacts (from the official record)
- Dorian Rose, PT, MS, PhD, FAPTA · 352-273-8307 · research@rxfunction.com
- Hannah Grimes · 904-528-3159 · Hannah.Grimes@brooksrehab.org
Similar studies in Florida
All diabetes studies in Florida →- RecruitingHealthy volunteersPhase 1
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Gilead Sciences
- Location
- Miami, FL + 2 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Amgen
- Location
- Aventura, FL + 1 other US site
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- Deerfield Beach, FL + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
Sun Pharmaceutical Industries Limited
- Location
- Miami Lakes, FL
- Eligibility basics
- Ages 18–80